Ignite Creation Date:
2024-07-17 @ 11:59 AM
Last Modification Date:
2024-10-26 @ 3:32 PM
Study NCT ID:
NCT06463028
Status:
NOT_YET_RECRUITING
Last Update Posted:
2024-06-17
First Post:
2024-06-11
Brief Title:
Sapanisertib and Serabelisib PIKTOR With Paclitaxel Serabelisib With Paclitaxel and Paclitaxel Alone in Patients With AdvancedRecurrent Endometrial Cancer
Sponsor:
Faeth Therapeutics
Organization:
Faeth Therapeutics
Conditions & Keywords Data
Conditions:
| Name |
|---|
| Endometrial Cancer |
Keywords:
| Name | View |
|---|---|
| Serabelisib | View |
| Sapanisertib | View |
| Paclitaxel | View |
| Taxol | View |
| Antineoplastic Agents | View |
| PI3K | View |
| AKT | View |
| mTOR | View |
| Dual PI3kmTOR inhibition | View |
| Genetic mutation | View |
| Cisplatin | View |
| Carboplatin | View |
| Genital Diseases | View |
| Endometrial Neoplasms | View |
| Advanced Endometrial Carcinoma | View |
| Recurrent Endometrial Carcinoma | View |
| Metastatic Endometrial Carcinoma | View |
| Endometrial Cancer | View |
| Endometrioid Carcinoma | View |
| Cancer of Endometrium | View |
| Cancer of the Endometrium | View |
| Carcinoma of Endometrium | View |
| Endometrial Carcinoma | View |
| Endometrium Cancer | View |
| Neoplasms Endometrial | View |
| Metabolism | View |
| Synthetic Lethality | View |
| Metabolism Programming | View |
| PIK3CA | View |